PURPOSE: To identify the maximum-tolerated dose and dose-limiting @entity137 (DLT) of weekly @entity2600 combined with @entity900 and radiation in @entity418 . @entity1 AND METHODS: Nineteen @entity1 with clinical stage II to III esophageal squamous cell or @entity420 were treated on this phase I trial. Induction chemotherapy with weekly @entity900 30 mg/m2 and @entity2600 65 mg/m2 was administered for four treatments during weeks 1 to 5. Radiotherapy was delivered weeks 8 to 13 in 1.8-Gy daily fractions to a dose of 50.4 Gy. @entity900 30 mg/m2 and escalating-dose @entity2600 (40, 50, 65, and 80 mg/m2) were administered on days 1, 8, 22, and 29 of radiotherapy. DLT was defined as a 2-week delay in radiotherapy for grade 3 to 4 @entity137 . RESULTS: Minimal @entity137 was observed during chemoradiotherapy, with no grade 3 or 4 @entity2910 , @entity294 , or @entity3136 . DLT caused by myelosuppression was seen in two of six @entity1 treated at the 80-mg/m2 dose level, thus @entity2600 65 mg/m2 was defined as the recommended phase II dose. @entity1282 improved or resolved after induction chemotherapy in 13 (81%) of 16 @entity1 who reported @entity1282 before therapy. Only one @entity1 (5%) required a feeding tube. Six complete responses (32%) were observed, including four pathologic complete responses in 15 @entity1 selected to undergo surgery (27%). CONCLUSION: @entity900 , @entity2600 , and concurrent radiotherapy can be administered on a convenient schedule with relatively minimal @entity137 and an acceptable rate of complete response in @entity418 . Further phase II evaluation of this regimen is ongoing. A phase III comparison to @entity1487 or @entity3907 -containing chemoradiotherapy should be considered.

Phase I trial of escalating-dose XXXX given weekly with @entity900 and concurrent radiotherapy in locally advanced @entity418 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['Dysphagia', 'dysphagia'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']
@entity2600 :: (MESH:C051890,Chemical) :: ['irinotecan']
